Literature DB >> 22528759

Combined common femoral artery endarterectomy with superficial femoral artery stenting plus Shuxuening Injection infusion for chronic lower extremity ischemia: 3-year results.

Hai Feng1, Xue-ming Chen, Chen-yu Li, Ren-ming Zhu, Jie Fang, Tian-you Wang.   

Abstract

OBJECTIVE: To investigate the efficacy and safety of combined common femoral artery (CFA) endarterectomy with superficial femoral artery (SFA) stenting plus Shuxuening Injection infusion in patients with complex multifocal arterial steno-obstructive lesions of the lower extremities.
METHODS: From March 2006 to March 2011, 104 lower limbs in 96 patients with multilevel peripheral arterial steno-occlusive disease, involving SFA as well as CFA and deep femoral artery (DFA) orifice, were treated by combined surgical with endovascular therapy, such as SFA stenting as an adjunct to CFA endarterectomy and patch angioplasty with the great saphenous vein. Before the end of the operation, 20 mL of Shuxuening Injection was infused through the catheter located in the treated artery. Technical and hemodynamic success, as well as primary and primary-assisted patency, was determined according to the Society for Vascular Surgery Guidelines. During follow-up, clinical status assessment, ankle-brachial index (ABI) test, and duplex Doppler ultrasound were administered every 6 months, and computed tomography angiography or magnetic resonance angiography was performed at 12, 24, and 36 months after discharge.
RESULTS: All patients underwent successful combined CFA endarterectomy with SFA stenting treatment. The average ABI after the combination treatment increased from pretreatment of 0.32±0.21 to 0.82±0.24 (P<0.01). No perioperative death and major limb amputations occurred. The mean duration of follow-up for 104 limbs from 96 patients was 1,180 days (range, 196-2,064 days). During follow-up, 5 patients died due to myocardial infarction, cerebral infarction, or pneumonia, and 5 patients were lost to follow-up. There were 21 cases (21.4%) of restenosis, with 15 that occurred in-stent and 6 near the distal end of the stent. A total of 18 (18.3%) reinterventions were performed, including 6 balloon angioplasty, 8 restenting procedures, 2 bypass surgeries, and 2 major limb amputations. The primary patency rates were 92.2%, 76.8%, and 61.3% at 12, 24, and 36 months, respectively, while the primary-assisted patency rates were 94.4%, 83.2%, and 75.6% at 12, 24, and 36 months, respectively.
CONCLUSION: The combined CFA endarterectomy with SFA stenting plus Shuxuening Injection infusion appears to offer a safe, less invasive, and effective treatment option to patients with chronic lower extremity ischemia due to complex multifocal peripheral artery disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528759     DOI: 10.1007/s11655-012-1113-z

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  28 in total

1.  Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials.

Authors:  M H Pittler; E Ernst
Journal:  Am J Med       Date:  2000-03       Impact factor: 4.965

2.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

3.  Comparison of costs of staged versus simultaneous lower extremity arterial hybrid procedures.

Authors:  James L Ebaugh; David Gagnon; Christopher D Owens; Michael S Conte; Joseph D Raffetto
Journal:  Am J Surg       Date:  2008-11       Impact factor: 2.565

Review 4.  A contemporary meta-analysis of Dacron versus polytetrafluoroethylene grafts for femoropopliteal bypass grafting.

Authors:  Hisato Takagi; Shin-Nosuke Goto; Masafumi Matsui; Hideaki Manabe; Takuya Umemoto
Journal:  J Vasc Surg       Date:  2010-05-14       Impact factor: 4.268

5.  Reporting standards and statistics for evaluating intervention.

Authors:  K A Myers
Journal:  Cardiovasc Surg       Date:  1995-10

6.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.

Authors:  Martin Schillinger; Schila Sabeti; Christian Loewe; Petra Dick; Jasmin Amighi; Wolfgang Mlekusch; Oliver Schlager; Manfred Cejna; Johannes Lammer; Erich Minar
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

7.  Hybrid therapy in patients with complex peripheral multifocal steno-obstructive vascular disease: two-year results.

Authors:  Antonio Raffaele Cotroneo; Roberto Iezzi; Giuseppe Marano; Paolo Fonio; Franco Nessi; Giovanni Gandini
Journal:  Cardiovasc Intervent Radiol       Date:  2007 May-Jun       Impact factor: 2.740

8.  Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.

Authors:  H Peters; M Kieser; U Hölscher
Journal:  Vasa       Date:  1998-05       Impact factor: 1.961

Review 9.  Ginkgo biloba for cerebral insufficiency.

Authors:  J Kleijnen; P Knipschild
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

10.  Stent placement for superficial femoral arterial occlusive disease in high-risk patients: preliminary results.

Authors:  Toshiya Nishibe; Yuka Kondo; Masayasu Nishibe; Akihito Muto; Alan Dardik
Journal:  Surg Today       Date:  2009-01-08       Impact factor: 2.549

View more
  2 in total

1.  Shuxuening injection protects against myocardial ischemia-reperfusion injury through reducing oxidative stress, inflammation and thrombosis.

Authors:  Ruiying Wang; Min Wang; Jiahui Zhou; Tianyuan Ye; Xueheng Xie; Dong Ni; Jingxue Ye; Qiaoling Han; Caixia Di; Liang Guo; Guibo Sun; Xiaobo Sun
Journal:  Ann Transl Med       Date:  2019-10

Review 2.  Chinese Herbal Medicine Alleviates Myocardial Ischemia/Reperfusion Injury by Regulating Endoplasmic Reticulum Stress.

Authors:  Wu-Lin Liang; Meng-Ru Cai; Ming-Qian Zhang; Shuang Cui; Tian-Rui Zhang; Wen-Hao Cheng; Yong-Hong Wu; Wen-Jing Ou; Zhan-Hong Jia; Shuo-Feng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-07       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.